Belgium - francia - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - atovaquone 250 mg; chlorhydrate de proguanil 100 mg - comprimé pelliculé - proguanil, combinations

Kanada - francia - Health Canada

mylan pharmaceuticals ulc - atovaquone; chlorhydrate de proguanil - comprimé - 250mg; 100mg - atovaquone 250mg; chlorhydrate de proguanil 100mg - antimalarials

Kanada - francia - Health Canada

teva canada limited - atovaquone; chlorhydrate de proguanil - comprimé - 250mg; 100mg - atovaquone 250mg; chlorhydrate de proguanil 100mg - antimalarials

Kanada - francia - Health Canada

glenmark pharmaceuticals canada inc. - atovaquone; chlorhydrate de proguanil - comprimé - 250mg; 100mg - atovaquone 250mg; chlorhydrate de proguanil 100mg - antimalarials

Belgium - francia - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline pharmaceuticals sa-nv - atovaquone 750 mg/5 ml - suspension buvable - 750 mg/5 ml - atovaquone 150 mg/ml - atovaquone

Európai Unió - francia - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - arthrite, rhumatoïde - immunosuppresseurs - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 et 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Svájc - francia - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - atovaquonum - suspension - atovaquonum 750 mg, alcohol benzylicus 50 mg, xanthani gummi, poloxamerum 188, saccharinum natricum corresp. natrium 0.95 mg, aromatica (vielfrucht) cum aurantii dulcis aetheroleum, aurantii dulcis aetheroleum concentratum, propylenglycolum, alcohol benzylicus 0.66 mg, vanillinum, acetaldehydum, ethylis butyras et amylis acetas, aqua purificata q.s. ad suspensionem pro 5 ml. - pneumonie à pneumocystis carinii - synthetika

Svájc - francia - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - atovaquonum, proguanili hydrochloridum - comprimés pelliculés - atovaquonum 250 mg, proguanili hydrochloridum 100 mg, hydroxypropylcellulosum substitutum humile, cellulosum microcristallinum, povidonum k 30, carboxymethylamylum natricum a, magnesii stearas, poloxamerum 188, Überzug: hypromellosum, e 171, macrogolum 400, e 172 (rubrum), macrogolum 8000, pro compresso obducto corresp. natrium max. 0.588 mg. - le paludisme - synthetika

Svájc - francia - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - atovaquonum, proguanili hydrochloridum - comprimés pelliculés - atovaquonum 62.5 mg, proguanili hydrochloridum 25 mg, hydroxypropylcellulosum substitutum humile, cellulosum microcristallinum, povidonum k 30, carboxymethylamylum natricum a, magnesii stearas, poloxamerum 188, Überzug: hypromellosum, e 171, macrogolum 400, e 172 (rubrum), macrogolum 8000, pro compresso obducto corresp. natrium max. 0.147 mg. - le paludisme - synthetika

Svájc - francia - Swissmedic (Swiss Agency for Therapeutic Products)

armeeapotheke - crofab - antivenin - antivenine